GILD

Business Context and Reporting Period

This Form 10-Q covers Gilead Sciences, Inc. for the three and nine months ended September 30, 1999. Gilead is a biopharmaceutical company focused on infectious, oncological, and hematological diseases. A material event during this period was the July 29, 1999, merger with NeXstar Pharmaceuticals, Inc., accounted for as a pooling of interests. Consequently, prior period financial data has been restated to reflect the combined entity.

Key Financial Metrics

Revenue Composition (Nine Months 1999): Product sales ($100.6M), Contract revenue ($12.1M), Royalty revenue ($7.4M). AmBisome accounted for approximately 89% of product sales.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 20.7% for the nine months ended September 30, 1999, compared to the prior year. This was driven primarily by a 24% increase in AmBisome sales and higher royalty revenues.
• Increased Losses: The net loss for the nine months ended September 30, 1999, widened significantly to $57.5 million from $26.1 million in the prior year. This deterioration was primarily due to $18.2 million in merger-related expenses associated with the NeXstar acquisition.
• Operating Expenses: Research and Development (R&D) expenses decreased to $81.7 million (from $92.6 million in 1998) due to reduced activities at the Boulder facility and lower involvement in TAMIFLU development, partially offset by increased spending on new candidates (adefovir, tenofovir). Selling, General, and Administrative (SG&A) expenses remained relatively flat.
• Liquidity: Cash and cash equivalents decreased by $30.3 million during the nine-month period, primarily due to operating losses and capital expenditures, partially offset by stock issuances.

Guidance, Outlook, and Risks

• Merger Integration: Management anticipates continued integration costs with NeXstar, though significant future merger-related expenses are not expected.
• Product Pipeline & Regulatory Risks:
  • TAMIFLU: Approved by the FDA in October 1999; royalties from this product are expected to become the majority of royalty revenue starting in 2000.
  • Adefovir Dipivoxil: An FDA Advisory Committee recommended against approval for AIDS treatment in November 1999. While the FDA is not bound by this, a rejection could delay profitability. Development for Hepatitis B continues.
• Financial Outlook: The company has never been profitable on a full-year basis and expects financial results to fluctuate. R&D expenses are expected to increase in late 1999 and 2000. Management believes existing capital resources are adequate for the foreseeable future.
• Year 2000 Compliance: The company has substantially completed its Y2K project with an estimated total cost of $2.2 million. Contingency plans are in place for critical systems.
• Foreign Currency: A significant portion of sales is denominated in European currencies; a stronger U.S. dollar could reduce revenue returns.

Investor Verification Checklist

• Merger Impact: Verify the sustainability of the $18.2 million merger-related charge and the timeline for realizing synergies from the NeXstar acquisition.
• AmBisome Dependency: Assess the risk of revenue concentration, as AmBisome represents ~89% of product sales and faces competition from lower-priced alternatives.
• Regulatory Status of Adefovir: Monitor the final FDA decision on adefovir dipivoxil for AIDS and the progress of the Hepatitis B program, given the recent negative advisory committee recommendation.
• TAMIFLU Royalties: Confirm the timing and magnitude of royalty inflows from Roche following the October 1999 approval of TAMIFLU.
• Cash Burn Rate: Evaluate the runway of the $307.4 million cash position against the projected increase in R&D spending and the historical operating loss trend.